YD BIO LTD (YDES) Fundamental Analysis & Valuation

NASDAQ:YDES • KYG983011076

Current stock price

7.43 USD
+0.14 (+1.92%)
Last:

This YDES fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. YDES Profitability Analysis

1.1 Basic Checks

  • In the past year YDES has reported negative net income.
YDES Yearly Net Income VS EBIT VS OCF VS FCFYDES Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

  • YDES's Return On Assets of -24.17% is fine compared to the rest of the industry. YDES outperforms 72.15% of its industry peers.
  • With a decent Return On Equity value of -27.74%, YDES is doing good in the industry, outperforming 77.56% of the companies in the same industry.
Industry RankSector Rank
ROA -24.17%
ROE -27.74%
ROIC N/A
ROA(3y)-12.91%
ROA(5y)N/A
ROE(3y)-169.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YDES Yearly ROA, ROE, ROICYDES Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

  • YDES has a Gross Margin of 30.45%. This is in the better half of the industry: YDES outperforms 72.15% of its industry peers.
  • YDES does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YDES Yearly Profit, Operating, Gross MarginsYDES Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. YDES Health Analysis

2.1 Basic Checks

  • YDES does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for YDES remains at a similar level compared to 1 year ago.
  • The debt/assets ratio for YDES has been reduced compared to a year ago.
YDES Yearly Shares OutstandingYDES Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
YDES Yearly Total Debt VS Total AssetsYDES Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • An Altman-Z score of 408.27 indicates that YDES is not in any danger for bankruptcy at the moment.
  • YDES has a Altman-Z score of 408.27. This is amongst the best in the industry. YDES outperforms 100.00% of its industry peers.
  • There is no outstanding debt for YDES. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 408.27
ROIC/WACCN/A
WACC9.21%
YDES Yearly LT Debt VS Equity VS FCFYDES Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

  • A Current Ratio of 1.86 indicates that YDES should not have too much problems paying its short term obligations.
  • YDES has a Current ratio of 1.86. This is in the lower half of the industry: YDES underperforms 78.34% of its industry peers.
  • YDES has a Quick Ratio of 1.36. This is a normal value and indicates that YDES is financially healthy and should not expect problems in meeting its short term obligations.
  • YDES's Quick ratio of 1.36 is on the low side compared to the rest of the industry. YDES is outperformed by 82.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.36
YDES Yearly Current Assets VS Current LiabilitesYDES Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1M 2M 3M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. YDES Growth Analysis

3.1 Past

  • YDES shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10100.00%.
  • The Revenue has grown by 45.79% in the past year. This is a very strong growth!
EPS 1Y (TTM)-10100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1082.61%
Revenue 1Y (TTM)45.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.34%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
YDES Yearly Revenue VS EstimatesYDES Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100K 200K 300K 400K 500K

More info and screens

Find the best growth stocksShow best growing peers

0

4. YDES Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for YDES. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YDES Price Earnings VS Forward Price EarningsYDES Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YDES Per share dataYDES EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 0.04 0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. YDES Dividend Analysis

5.1 Amount

  • No dividends for YDES!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

YDES Fundamentals: All Metrics, Ratios and Statistics

YD BIO LTD

NASDAQ:YDES (4/2/2026, 8:02:22 PM)

7.43

+0.14 (+1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-16
Earnings (Next)05-04
Inst Owners0.47%
Inst Owner Change-19.33%
Ins Owners77.13%
Ins Owner Change0%
Market Cap523.96M
Revenue(TTM)510.40K
Net Income(TTM)-1.41M
AnalystsN/A
Price TargetN/A
Short Float %0.27%
Short Ratio1.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1026.57
P/FCF N/A
P/OCF N/A
P/B 102.98
P/tB 239.61
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.01
BVpS0.07
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.17%
ROE -27.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.45%
FCFM N/A
ROA(3y)-12.91%
ROA(5y)N/A
ROE(3y)-169.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.36
Altman-Z 408.27
F-ScoreN/A
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1082.61%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)45.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20497.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-134.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.28%
OCF growth 3YN/A
OCF growth 5YN/A

YD BIO LTD / YDES Fundamental Analysis FAQ

What is the ChartMill fundamental rating of YD BIO LTD (YDES) stock?

ChartMill assigns a fundamental rating of 3 / 10 to YDES.


Can you provide the valuation status for YD BIO LTD?

ChartMill assigns a valuation rating of 0 / 10 to YD BIO LTD (YDES). This can be considered as Overvalued.


What is the profitability of YDES stock?

YD BIO LTD (YDES) has a profitability rating of 2 / 10.


What is the financial health of YD BIO LTD (YDES) stock?

The financial health rating of YD BIO LTD (YDES) is 6 / 10.